Sorafenib sensitization in tumor therapy by iron overload and AMPK activation
- 17 May 2024
- journal article
- research article
- Published by Tsinghua University Press in Nano Research
- Vol. 17 (7) , 6386-6399
Abstract
Sorafenib, as a first-line drug for advanced hepatocellular carcinoma (HCC), could trigger ferroptosis by inhibiting cystine/glutamate transporter. However, low-level intracellular iron and insufficient activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) confer impaired response to sorafenib. In this study, a unique sorafenib nanocomposite dexterously modified with Fe-Material of Institut Lavoisier (sora@Fe-MIL) was synthesized to escalate intracellular iron level and activate AMPK, further potentiating the ferroptotic effect of sorafenib. Remarkably, this strategic deployment of sora@Fe-MIL triggered an extensive demise of cancer cells, while manifesting negligible deleterious impact on normal cells. Two prominent ferroptosis biomarkers, glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), underwent pronounced downregulation, underscoring the efficacy of this strategy in inducing ferroptosis. Furthermore, the bioactivity of AMPK was considerably elevated, and its downstream targets were conspicuously inhibited by the treatment with sora@Fe-MIL. Using orthotopic HCC animal models, we observed a substantial suppression of primary in situ tumor growth, and ribonucleic acid (RNA) sequencing elucidated an elevated degree of ferroptosis and AMPK activation with the treatment of sora@Fe-MIL. In conclusion, we proposed that the meticulously designed strategy for secure and efficacious iron release and AMPK activation could significantly potentiate the ferroptotic impact of sorafenib, thus resuscitating its therapeutic response in HCC patients.Keywords
This publication has 69 references indexed in Scilit:
- Disrupting Intracellular Iron Homeostasis by Engineered Metal‐Organic Framework for Nanocatalytic Tumor Therapy in Synergy with Autophagy Amplification‐Promoted FerroptosisAdvanced Functional Materials, 2023
- Ferroptosis: The Entanglement between Traditional Drugs and Nanodrugs in Tumor TherapyAdvanced Healthcare Materials, 2023
- Metformin Carbon Dots for Promoting Periodontal Bone Regeneration via Activation of ERK/AMPK PathwayAdvanced Healthcare Materials, 2021
- NIR‐Actuated Remote Activation of Ferroptosis in Target Tumor Cells through a Photothermally Responsive Iron‐Chelated Biopolymer NanoplatformAngewandte Chemie International Edition, 2021
- A Metal‐Organic Framework (MOF) Fenton Nanoagent‐Enabled Nanocatalytic Cancer Therapy in Synergy with Autophagy InhibitionAdvanced Materials, 2020
- Bovine serum albumin gel/polyelectrolyte complex of hyaluronic acid and chitosan based microcarriers for Sorafenib targeted deliveryJournal of Applied Polymer Science, 2020
- Enhanced Drug Delivery by Dissolution of Amorphous Drug Encapsulated in a Water Unstable Metal–Organic Framework (MOF)Angewandte Chemie International Edition, 2019
- Targeting AMP‐activated kinase impacts hepatocellular cancer stem cells induced by long‐term treatment with sorafenibMolecular Oncology, 2019
- Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer TherapyAdvanced Materials, 2017
- Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cellsHepatology, 2015